ABRAXANE® TO THE RESCUE

The recent approval by the FDA of ABRAXANE® in combination with GEMZAR® (Gemcitabine) for the first line treatment of patients with metastatic Adenocarcinoma of the Pancreas gives the Oncology Health Care Providers a much needed option to treat this group of patients. With a significant improvement in the Overall Survival, Progression Free Survival and Response Rates, ABRAXANE® combination will very likely replace the more toxic FOLFIRI regimen by virtue of its efficacy and tolerability.